<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03298581</url>
  </required_header>
  <id_info>
    <org_study_id>71542610</org_study_id>
    <nct_id>NCT03298581</nct_id>
  </id_info>
  <brief_title>Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis</brief_title>
  <official_title>An Open-label Safety Study to Assess the Multiple-dose Pharmacokinetics and Potential for Adrenal Suppression Following Topical Treatment With Halobetasol Propionate 0.05% Topical Spray Applied Twice Daily for 28 Days in Patients With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharmaceutical Industries Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novum Pharmaceutical Research Services</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Pharmaceutical Industries Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and&#xD;
      potential for adrenal suppression following topical treatment with halobetasol propionate&#xD;
      0.05% spray applied twice-daily in adult patients with moderate to severe plaque psoriasis.&#xD;
      At least 40 eligible patients with plaque psoriasis that satisfy all eligibility criteria&#xD;
      will be enrolled into the study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and&#xD;
      potential for adrenal suppression following topical treatment with halobetasol propionate&#xD;
      0.05% spray applied twice-daily in adult patients with moderate to severe plaque psoriasis.&#xD;
      At least 40 eligible patients with plaque psoriasis that satisfy all eligibility criteria&#xD;
      will be enrolled into the study. Patients must be overall in good health and should have a&#xD;
      current diagnosis of moderate to severe plaque psoriasis with Investigator Global Assessment&#xD;
      (IGA) score of at least 3 or 4. Patients will be stratified by age with:&#xD;
&#xD;
      Cohort 1: At least 20 patients 18 years of age and older with ≥ 20% body surface area (BSA)&#xD;
      affected Cohort 2: At least 20 patients 12-16 years and 11 months of age with ≥ 10% BSA&#xD;
      affected Cohort 2 will initiate enrollment once all enrolled patients in Cohort 1 have&#xD;
      completed the study and a safety analysis has been reviewed by the Medical Monitor and&#xD;
      approved by the Novum Independent Institutional Review Board (NIIRB). Sites will not begin&#xD;
      enrollment of patients in Cohort 2 until the site is notified by email that the safety&#xD;
      analysis for Cohort 1 has been reviewed and approved. Confirmation of email receipt will be&#xD;
      required from each Investigator before enrollment of Cohort 2 can begin. Each cohort will be&#xD;
      enrolled based on the availability of patients. Each cohort will be reviewed for the&#xD;
      potential of HPA axis suppression. The Medical Monitor or NIIRB may discontinue the study at&#xD;
      any time if safety concerns are found. If 6 or more patients in Cohort 1 experience HPA axis&#xD;
      suppression, then enrollment for Cohort 1 will be stopped. Cohort 2 will not be initiated if&#xD;
      6 or more patients enrolled in Cohort 1 experience HPA axis suppression or 30% or more of the&#xD;
      final enrolled number of patients in Cohort 1 experience HPA axis suppression. If 6 or more&#xD;
      patients in Cohort 2 experience HPA axis suppression, then enrollment for Cohort 2 will be&#xD;
      stopped. If the study is stopped at any time, patients currently enrolled will be contacted&#xD;
      via phone and instructed to discontinue study product immediately. Patients will be&#xD;
      instructed to return for their next scheduled visit for cortisol response testing. Sites will&#xD;
      follow up with patients and monitor for HPA axis suppression. All patients will be followed&#xD;
      until cortisol levels are normal.&#xD;
&#xD;
      Patients will be instructed to apply topical spray twice daily onto the affected skin areas&#xD;
      for 28 days. Patients will be instructed not to rub over the affected area after application&#xD;
      of spray Patients will apply the morning dose of the study product in the clinic at each&#xD;
      clinic visit and at home during non-clinic visits. A phone call will be made approximately 14&#xD;
      days after the patient has completed dosing to follow-up on any new adverse events that may&#xD;
      have occurred&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor decision&#xD;
  </why_stopped>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">January 31, 2018</completion_date>
  <primary_completion_date type="Actual">January 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, single treatment arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the IGA score at Day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Patients will be considered to have shown improvement in disease severity if the IGA score decreases by at least one unit from the baseline score, and will be considered a treatment success if the IGA score is either 0 (clear) or 1 (minimal).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypothalamic Pituitary Adrenal (HPA) Axis suppression</measure>
    <time_frame>28 days</time_frame>
    <description>Hypothalamic Pituitary Adrenal (HPA) Axis Response to Cosyntropin demonstrating the absence or presence, defined by 30 minute post- CortrosynTM injection level cortisol level of ≤18 mcg/100 mL, at the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Halobetasol propionate spray 0.05%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will instructed o apply halobetasol spray twice daily for 14 days and not to rub over the affected area after application of spray.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Halobetasol Propionate</intervention_name>
    <description>Experimental: Treatment with topical halobetasol spray 0.05% Patients will instructed o apply halobetasol spray twice daily for 28 days and not to rub over the affected area after application of spray.</description>
    <arm_group_label>Halobetasol propionate spray 0.05%</arm_group_label>
    <other_name>Topical treatment with Halobetasol spray</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or non-pregnant, non-lactating females:&#xD;
&#xD;
               -  Cohort 1: 18 years of age and older&#xD;
&#xD;
               -  Cohort 2: 12-16 years and 11 months of age (Cohort 2 will not begin enrollment&#xD;
                  until review and approval of safety information from Cohort 1.)&#xD;
&#xD;
          2. If female and of childbearing potential, prepared to abstain from sexual intercourse&#xD;
             or use a reliable method of contraception during the study (e.g., condom, IUD, oral,&#xD;
             transdermal or injected hormonal contraceptives). Female patients using hormonal&#xD;
             contraceptives should have been on the same product/dosing regimen for at least 28&#xD;
             days before baseline and should not change this regimen during the study.&#xD;
&#xD;
          3. Signed informed consent form that meets all criteria of current FDA regulations. For a&#xD;
             patient considered to be a minor in the state he/she lives and is enrolled, the parent&#xD;
             or legal guardian will be required to sign the consent form and the patient will sign&#xD;
             an IRB approved &quot;assent to participate&quot; form. Approved informed consent and assent&#xD;
             forms specific to each cohort will be required.&#xD;
&#xD;
          4. Patients with a definite clinical diagnosis of stable plaque psoriasis with:&#xD;
&#xD;
               -  Cohort 1: 18 years of age and older with ≥ 20% BSA affected (excluding the face,&#xD;
                  scalp, groin, axillae and other intertriginous areas)&#xD;
&#xD;
               -  Cohort 2: 12-16 years and 11 months of age with ≥ 10% BSA affected (excluding the&#xD;
                  face, scalp, groin, axillae and other intertriginous areas)&#xD;
&#xD;
          5. Investigator Global Assessment (IGA) score of 3 (Moderate) or 4 (Severe).&#xD;
&#xD;
          6. Patients in Cohort 2 must weigh a minimum of 24 kg.&#xD;
&#xD;
          7. Results from a cortisol response test that are considered normal and show no evidence&#xD;
             of any abnormal HPA function or adrenal response. Patients must fulfill all of the&#xD;
             following stipulations:&#xD;
&#xD;
               1. Basal (pre-Cortrosyn™ injection) cortisol concentration ≥ 5 mcg/100 mL.&#xD;
&#xD;
               2. 30-minute post-injection cortisol level is at least 7 mcg/100 mL greater than the&#xD;
                  basal level (≥ basal value + 7).&#xD;
&#xD;
               3. Post-stimulation level &gt; 18 mcg/100 mL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant, nursing, planning to become pregnant during the duration of&#xD;
             the study, or if of childbearing potential and sexually active and not prepared to use&#xD;
             appropriate contraceptive methods to avoid pregnancy.&#xD;
&#xD;
          2. Lacks stable diagnosis of plaque psoriasis or has been diagnosed with mild plaque&#xD;
             psoriasis.&#xD;
&#xD;
          3. IGA score &lt; 3.&#xD;
&#xD;
          4. Plaque psoriasis with a BSA involvement &lt; 20% for Cohort 1 or &lt; 10% for Cohort 2.&#xD;
&#xD;
          5. Current diagnosis of types of psoriasis other than stable plaque psoriasis (i.e.,&#xD;
             erythrodermic, exfolative or pustular psoriasis).&#xD;
&#xD;
          6. Results from a cortisol response test that show evidence of any abnormal HPA function&#xD;
             or adrenal response:&#xD;
&#xD;
               1. Basal (pre-CortrosynTM injection) cortisol concentration &lt; 5 mcg/100 mL.&#xD;
&#xD;
               2. 30-minute post-injection cortisol level is less than 7 mcg/100 mL greater than&#xD;
                  the basal level (&lt; basal value + 7).&#xD;
&#xD;
               3. Post-stimulation level ≤ 18 mcg/100 mL.&#xD;
&#xD;
          7. Patient has a history of plaque psoriasis that has been unresponsive to topical&#xD;
             corticosteroid therapy.&#xD;
&#xD;
          8. Any condition (i.e., sunburn, atopic or contact dermatitis, etc.) that, in the&#xD;
             Investigator's opinion, may interfere with the clinical assessments of the signs and&#xD;
             symptoms of plaque psoriasis.&#xD;
&#xD;
          9. History of prolonged bleeding or a past diagnosis of bleeding disorders and/or history&#xD;
             of blood loss exceeding 450 mL (including blood donations) within 1 month before the&#xD;
             study.&#xD;
&#xD;
         10. Patient with poor peripheral venous access.&#xD;
&#xD;
         11. History of mastectomy or lymphatic insufficiency of the upper limb (patient is&#xD;
             eligible if blood can be taken from the arm opposite the site of surgery or&#xD;
             condition).&#xD;
&#xD;
         12. History of allergy or sensitivity to corticosteroids or history of any drug&#xD;
             hypersensitivity or intolerance that in the opinion of the Investigator, would&#xD;
             compromise the safety of the patient or the results of the study.&#xD;
&#xD;
         13. Patient has a significant history or current evidence of chronic infectious disease,&#xD;
             system disorder, Netherton's Syndrome, uncontrolled diabetes, organ disorder or&#xD;
             insufficiency, immunosuppression (from medical treatment or disease) or other medical&#xD;
             condition (including active or recurrent bacterial, viral or fungal infection or open&#xD;
             wounds) that, in the Investigator's opinion, would place the study patient at undue&#xD;
             risk by participation in the study or as an unsuitable candidate for the study.&#xD;
&#xD;
         14. Patients who have a history of or current diagnosis of glaucoma or posterior&#xD;
             subcapsular cataracts or any other ocular condition that, in the opinion of the&#xD;
             Investigator, would place study patient at undue risk.&#xD;
&#xD;
         15. Patient is currently receiving or has received any radiation therapy or&#xD;
             anti-neoplastic agents within 3 months before baseline.&#xD;
&#xD;
         16. Use within 4 weeks before baseline of 1) oral or intravenous corticosteroids, 2)&#xD;
             UVA/UVB therapy, 3) PUVA (psoralen plus ultraviolet A therapy, 4) prescription&#xD;
             strength anti-inflammatory agents, 5) topical tacrolimus or pimecrolimus or 6) any&#xD;
             other systemic psoriasis treatment.&#xD;
&#xD;
         17. Known history of hypothalamic-pituitary-adrenal axis impairment or any other&#xD;
             disturbance of the adrenal function (e.g., Cushing or Addison disease).&#xD;
&#xD;
         18. Use of tanning booths or nonprescription UV light source within 2 weeks before&#xD;
             baseline.&#xD;
&#xD;
         19. Use within 8 weeks before baseline of 1) immunomodulators or immunosuppressive&#xD;
             therapies, 2) interferon or 3) systemic retinoids.&#xD;
&#xD;
         20. Use within 14 days before baseline of 1) systemic antibiotics, 2) calcipotriene or&#xD;
             other Vitamin D preparations, or 3) topical retinoids.&#xD;
&#xD;
         21. Patients who have used topical treatments, prescription or over the counter,&#xD;
             including:&#xD;
&#xD;
               1. Any topical anti-psoriatic therapeutic agents of any kind within the 2 weeks&#xD;
                  before baseline.&#xD;
&#xD;
               2. Any topical corticosteroids within the 2 weeks before baseline.&#xD;
&#xD;
               3. Any antibacterial, medicated and/or astringent washes, soaps, pads or&#xD;
                  moisturizers within 3 days before baseline.&#xD;
&#xD;
               4. High strength (20% or above) alpha-hydroxy acid or any kind of peel or other&#xD;
                  procedures (e.g., laser hair removal) within 30 days before baseline.&#xD;
&#xD;
               5. Any topical products (i.e., sunscreens, lotions, creams), except for bland&#xD;
                  emollient (moisturizer) within 24 hours before baseline.&#xD;
&#xD;
               6. Topical antibiotics in the treatment area within 7 days before baseline.&#xD;
&#xD;
               7. New regimens of beta blockers.&#xD;
&#xD;
               8. Lithium preparations within 2 weeks before baseline.&#xD;
&#xD;
               9. Anti-malarial agents within 2 weeks before baseline.&#xD;
&#xD;
         22. Patient has been treated within 6 months before baseline with any biological therapies&#xD;
             for psoriasis.&#xD;
&#xD;
         23. Inability to understand the protocol requirements, instructions, and study related&#xD;
             restrictions, the nature, scope, and possible consequences of the clinical study.&#xD;
&#xD;
         24. Unlikely to comply with the protocol requirements, instructions, and study-related&#xD;
             restrictions, such as uncooperative attitude, inability to return for follow-up&#xD;
             visits, and improbability of completing the clinical study.&#xD;
&#xD;
         25. Receipt of any drug as part of a research study within 30 days before baseline.&#xD;
&#xD;
         26. The patient is a member of the investigational study staff or a member of the family&#xD;
             of the investigational study staff.&#xD;
&#xD;
         27. Previous participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajinder k Jalali, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sun Pharmaceutical Industries Limited</affiliation>
  </overall_official>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 19, 2017</study_first_submitted>
  <study_first_submitted_qc>September 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2017</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
    <mesh_term>Halobetasol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03298581
org study id: 71542610
nct id: NCT03298581
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and
      potential for adrenal suppression following topical treatment with halobetasol propionate
      0.05% spray applied twice-daily in adult patients with moderate to severe plaque psoriasis.
      At least 40 eligible patients with plaque psoriasis that satisfy all eligibility criteria
      will be enrolled into the study
This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and
      potential for adrenal suppression following topical treatment with halobetasol propionate
      0.05% spray applied twice-daily in adult patients with moderate to severe plaque psoriasis.
      At least 40 eligible patients with plaque psoriasis that satisfy all eligibility criteria
      will be enrolled into the study. Patients must be overall in good health and should have a
      current diagnosis of moderate to severe plaque psoriasis with Investigator Global Assessment
      (IGA) score of at least 3 or 4. Patients will be stratified by age with:

      Cohort 1: At least 20 patients 18 years of age and older with ≥ 20% body surface area (BSA)
      affected Cohort 2: At least 20 patients 12-16 years and 11 months of age with ≥ 10% BSA
      affected Cohort 2 will initiate enrollment once all enrolled patients in Cohort 1 have
      completed the study and a safety analysis has been reviewed by the Medical Monitor and
      approved by the Novum Independent Institutional Review Board (NIIRB). Sites will not begin
      enrollment of patients in Cohort 2 until the site is notified by email that the safety
      analysis for Cohort 1 has been reviewed and approved. Confirmation of email receipt will be
      required from each Investigator before enrollment of Cohort 2 can begin. Each cohort will be
      enrolled based on the availability of patients. Each cohort will be reviewed for the
      potential of HPA axis suppression. The Medical Monitor or NIIRB may discontinue the study at
      any time if safety concerns are found. If 6 or more patients in Cohort 1 experience HPA axis
      suppression, then enrollment for Cohort 1 will be stopped. Cohort 2 will not be initiated if
      6 or more patients enrolled in Cohort 1 experience HPA axis suppression or 30% or more of the
      final enrolled number of patients in Cohort 1 experience HPA axis suppression. If 6 or more
      patients in Cohort 2 experience HPA axis suppression, then enrollment for Cohort 2 will be
      stopped. If the study is stopped at any time, patients currently enrolled will be contacted
      via phone and instructed to discontinue study product immediately. Patients will be
      instructed to return for their next scheduled visit for cortisol response testing. Sites will
      follow up with patients and monitor for HPA axis suppression. All patients will be followed
      until cortisol levels are normal.

      Patients will be instructed to apply topical spray twice daily onto the affected skin areas
      for 28 days. Patients will be instructed not to rub over the affected area after application
      of spray Patients will apply the morning dose of the study product in the clinic at each
      clinic visit and at home during non-clinic visits. A phone call will be made approximately 14
      days after the patient has completed dosing to follow-up on any new adverse events that may
      have occurred
allocation: N/A
intervention model: Single Group Assignment
intervention model description: Open label, single treatment arm study
primary purpose: Treatment
masking: None (Open Label)
measure: Change from baseline in the IGA score at Day 28
time frame: 28 days
description: Patients will be considered to have shown improvement in disease severity if the IGA score decreases by at least one unit from the baseline score, and will be considered a treatment success if the IGA score is either 0 (clear) or 1 (minimal).
measure: Hypothalamic Pituitary Adrenal (HPA) Axis suppression
time frame: 28 days
description: Hypothalamic Pituitary Adrenal (HPA) Axis Response to Cosyntropin demonstrating the absence or presence, defined by 30 minute post- CortrosynTM injection level cortisol level of ≤18 mcg/100 mL, at the end of treatment.
arm group label: Halobetasol propionate spray 0.05%
arm group type: Experimental
description: Patients will instructed o apply halobetasol spray twice daily for 14 days and not to rub over the affected area after application of spray.
intervention type: Drug
intervention name: Halobetasol Propionate
description: Experimental: Treatment with topical halobetasol spray 0.05% Patients will instructed o apply halobetasol spray twice daily for 28 days and not to rub over the affected area after application of spray.
arm group label: Halobetasol propionate spray 0.05%
other name: Topical treatment with Halobetasol spray
criteria: 
gender: All
minimum age: 12 Years
maximum age: 70 Years
healthy volunteers: No
last name: Rajinder k Jalali, MD
role: Study Director
affiliation: Sun Pharmaceutical Industries Limited
responsible party type: Sponsor
mesh term: Psoriasis
mesh term: Clobetasol
mesh term: Halobetasol
sharing ipd: Undecided